

BCCA Protocol Summary for Etoposide-Cisplatin Protocol for Germ Cell Cancers

Protocol Code

GUEP

Tumour Group

Genitourinary

Contact Physician

Dr. Heidi Martins (VICC)

GU Systemic Therapy Contacts

Dr. Nevin Murray (VCC)

ELIGIBILITY:

- Good prognosis seminoma or nonseminoma (international consensus prognostic [Cambridge] classification) if there are contraindications for GUBEP
- AFP less than 1000 mcg/L and hCG less than 5000 unit/L and LDH less than 1.5 x normal
- or pure seminoma

EXCLUSIONS:

- Mediastinal primary nonseminoma
- Intermediate or poor prognosis testicular cancer according to the IGCCCG classification
- Inadequate renal function (calculated creatinine clearance less than 40 mL/min) (relative contraindication)
- Inadequate hematologic function

It is strongly recommended that all patients with metastatic germ cell tumours should be presented in GU tumour group conference.

TESTS:

- Baseline: CBC and differential, platelets, liver enzymes (including LDH), creatinine, electrolytes, magnesium, calcium, AFP, hCG, random glucose
- Consider baseline audiogram for pretreatment hearing impairment.
- Consider prechemotherapy sperm count and banking if fertility is an issue.
- Before each cycle: CBC and differential, platelets, creatinine, LDH, AFP, hCG, magnesium, electrolytes, random glucose
- Repeat CBC on day 5 if ANC on day 1 less than $1 \times 10^9/L$ (not required on day 5 of the first cycle)
- Repeat creatinine on day 5 if creatinine on day 1 greater than the upper limit of normal
- Repeat abnormal tests every 21 days (scans optional if markers responding appropriately)

PREMEDICATIONS:

- Antiemetic protocol for highly emetogenic chemotherapy protocols (see SCNAUSEA).

TREATMENT:

- **Cycle length 21 Days regardless of ANC**
- **Duration: 4 cycles (3 cycles if adjuvant)**

Agent	Dose	BCCA Administration Standard	Duration
Pre-Hydration		IV 1000 mL NS with 20 mEq potassium chloride and 2 g magnesium sulfate over 1 hour	days 1 to 5
Etoposide	100 mg/m ²	IV in 500 mL NS over 45 minutes (use non-PVC equipment)	days 1 to 5
Cisplatin	20 mg/m ²	IV in 100 mL NS over 30 minutes	days 1 to 5
Post-Hydration		IV 500 mL NS over 30 minutes	days 1 to 5
Total hydration:		IV 2100 mL NS	

NOTE: Treatment should be given on 5 consecutive days.

DOSE MODIFICATIONS:

- No dose reduction or delay is permitted for counts, except omit Day 5 etoposide if WBC still not recovered (ANC less than $1 \times 10^9/L$) by Day 5.
- This program is given with curative intent and any delay or dose reduction may have serious implications. In the event of elevated creatinine (e.g. greater than 200 micromol/L), neutropenic fever or low platelets, phone consultation with a contact physician is recommended.
- Prophylactic use of filgrastim is not recommended.
- Filgrastim is indicated in patients receiving their second or subsequent cycle of GUBEP who have had an episode of neutropenic fever or who have not recovered their neutrophil count by Day 5.

PRECAUTIONS:

1. **Hypersensitivity:** Monitor infusion of etoposide for the first 15 minutes for signs of hypotension. Hypersensitivity reactions have also been reported for cisplatin. Refer to BCCA Hypersensitivity Guidelines.
2. **Extravasation:** Etoposide causes irritation if extravasated. Refer to BCCA Extravasation Guidelines.
3. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
4. **Renal Toxicity:** Nephrotoxicity is common with cisplatin. Strongly encourage oral hydration. If oral hydration is not possible (e.g. excessive nausea), IV hydration is indicated. Avoid nephrotoxic drugs such as aminoglycoside antibiotics.

Call Dr. Heidi Martins or tumour group delegate at (250) 370 8228 or 1-800 670 3322 with any problems or questions regarding this treatment program.

Date activated: 28 Apr 1989

Date revised: 01 June 2011 (Infusion section revised)

References:

1. International germ cell consensus collaborative group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. *J Clin Oncol* 15:564-603, 1997
2. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. *J Clin Oncol* 1989;7:387-91.
3. de Wit R, Roberts JT, Wilkinson P, et al. Final analysis demonstrating the equivalence of 3 BEP vs 4 cycles and the 5 day schedule vs 3 days per cycle in good prognosis germ cell cancer. An EORTC/MRC phase III study. *Proc Am Soc Clin Oncol* 2000;19a:326a (abstract 1281).